Alvogen Inc., of Pine Brook, N.J., and Synthon NV, of Nijmegen, the Netherlands, said they concluded the decentralized procedures for glatiramer acetate 40 mg/ml pre-filled syringe for the treatment of relapsing forms of multiple sclerosis and have received regulatory approval in Europe. The three-times-a-week drug is a therapeutically equivalent version of the originator medicine Copaxone (glatiramer acetate, Teva Pharmaceutical Industries Ltd.). A once-daily subcutaneous 20-mg/ml prefilled syringe already is marketed in Europe under the brand name Remurel.